A Phase 3 Clinical Trial to Evaluate Efficacy and Safety of Twice-daily Applications of Delgocitinib Cream 20 mg/g Compared With Cream Vehicle for a 16-week Treatment Period in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema (DELTA TEEN)
Latest Information Update: 31 Jul 2025
At a glance
- Drugs Delgocitinib (Primary)
- Indications Eczema
- Focus Registrational; Therapeutic Use
- Acronyms DELTA-TEEN
- Sponsors LEO Pharma
Most Recent Events
- 04 Feb 2025 Results presented in a LEO Pharma A/S media release
- 04 Feb 2025 Primary endpoint has been met (IGA-CHE treatment success at Week 16) , according to a LEO Pharma A/S media release
- 04 Feb 2025 According to a LEO Pharma A/S media release, company announced today the positive results of the DELTA TEEN trial.